Literature DB >> 2499131

Do parenteral nutrition solutions with high concentrations of branched-chain amino acids offer significant benefits to stressed patients?

K M Teasley1, R L Buss.   

Abstract

The critically ill, stressed patient has been characterized as having altered cellular metabolism. Altered protein metabolism is manifested as negative nitrogen balance, reduced whole-body protein synthesis, and increased proteolysis. An increased oxidation of the branched-chain amino acids (BCAA) leucine, isoleucine, and valine has also been observed. Exogenous administration of BCAA as part of a total parenteral nutrition (TPN) regimen has been proposed to compensate for the altered protein metabolism in the stressed patient by sparing endogenous sources of BCAA, thereby reducing skeletal muscle catabolism and increasing protein synthesis. Numerous clinical studies have been performed investigating this theory. The results are controversial. Differences in study outcomes appear to be related to study design, especially patient selection. Our review of those studies which were randomized, prospective, and controlled indicates that an improvement in nitrogen retention and visceral protein status can be achieved in stress-stratified patients who receive a TPN regimen containing a BCAA-enriched formula. The significance of these outcomes on morbidity, length of hospital stay, and mortality has not been evaluated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499131     DOI: 10.1177/106002808902300510

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  2 in total

Review 1.  Immunonutrition and enteral hyperalimentation of critically ill patients.

Authors:  S A McClave; C C Lowen; H L Snider
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

Review 2.  The role of skeletal muscle in the pathogenesis of altered concentrations of branched-chain amino acids (valine, leucine, and isoleucine) in liver cirrhosis, diabetes, and other diseases.

Authors:  M Holeček
Journal:  Physiol Res       Date:  2021-05-12       Impact factor: 1.881

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.